Background {#Sec1}
==========

Nocturia is the complaint that the individual has to wake at night one or more times to void \[[@CR1]\]. It can result from a range of factors, including behavioural influences, sleep disturbances, lower urinary tract dysfunction and altered fluid or salt homeostasis. Nocturia is prevalent in the general population and is known to increase in severity with age. 77% of people aged 60 and above experience some degree of nocturia with no difference seen between men and women \[[@CR2]\]. Nocturia impacts greatly on quality of life (QoL), potentially due to fatigue, cognitive dysfunction and disturbed emotional health \[[@CR3]\]. Furthermore, severe nocturia may be associated with cardiovascular disease, autonomic disease, obstructive sleep apnoea and chronic kidney disease \[[@CR4]\], and potentially a higher risk of mortality \[[@CR5]\]. A very high proportion of MS patients have lower urinary tract symptoms (LUTS) \[[@CR6]\]. LUTS are a substantial problem in MS, and nocturia is a particularly prominent symptom with substantial detrimental impact on QoL \[[@CR7]\].

Current treatments for nocturia include managing fluid intake, timed diuretics, desmopressin, antimuscarinic drugs, bedtime sedatives and miscellaneous compounds \[[@CR8]\]. Desmopressin is indicated for treatment of nocturia in MS \[[@CR9]\]. However, desmopressin can cause hyponatraemia \[[@CR10]\] and has been associated with hyponatraemic convulsions \[[@CR11], [@CR12]\]. Indeed, it is recommended that tri-cyclic antidepressants (commonly used in MS patients) are avoided when using Desmopressin to reduce the risk of hyponatraemia (British National Formulary). This can also potentially be an issue with diuretics. Antimuscarinics are known to cause dry mouth, constipation, swallowing difficulty and confusion. Patients taking sedatives can experience hangover sedation, while elderly subjects are at risk of cognitive impairment \[[@CR13]\]. These side effects and poor efficacy mean that clinicians are sometimes reluctant to initiate treatment for nocturia.

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone secreted primarily at night by the pineal gland. It regulates circadian rhythms and reduces smooth muscle spontaneous activity, including that found in the bladder \[[@CR14]\]. Melatonin tablets taken before bedtime may reduce nocturia in a subgroup of patients with benign prostate enlargement \[[@CR15]\]. In elderly patients with nocturia, levels of severity and QoL improve with melatonin use \[[@CR16]\]. In MS, sleep quality is commonly reduced as a consequence of a wide range of sleep abnormalities, of which nocturia is only one example. In MS there can be an impairment of endogenous melatonin secretion \[[@CR17], [@CR18]\], and administration of oral melatonin improves reduced sleep quality in MS patients \[[@CR19]\].

We hypothesised that bedtime administration of a melatonin sustained-release tablet will improve clinical nocturia in patients with MS. We previously published the protocol of the "Melatonin for nocturia in MS (MeNiMS)" study to evaluate this hypothesis \[[@CR20]\], and the current study reports the findings. We chose a low dose of 2 mg, as melatonin levels negatively correlate with multiple sclerosis activity in humans, and alterations in endogenous melatonin have been proposed potentially to affect MS relapses \[[@CR21]\]. The primary aim was to evaluate the effect of melatonin on mean number of nocturia episodes per night in MS patients. The secondary aims included: 1) improvement in QoL, 2) safety, 3) LUTS, 4) sleep quality and 5) total voided (urinated) volume and mean volume per void. A qualitative study was also included, which will be reported separately.

Methods {#Sec2}
=======

The detailed study protocol has previously been published \[[@CR20]\]. In brief, male and female patients aged ≥18 were recruited at Southmead Hospital, Bristol, UK. Each patient had a confirmed neurological diagnosis of MS as per the 2010 McDonald MS Criteria \[[@CR22]\]. They also reported at least one episode of nocturia every night on the International Consultation on Incontinence Questionnaires (ICIQ) Nocturia questionnaire (ICIQ-N \[[@CR23]\]). Patients were excluded if they had (i) an indwelling urinary catheter; (ii) used desmopressin or investigational medications in the month preceding randomization; (iii) taken antimuscarinic or diuretic medication, unless used long-term prior to study (\> 3 months) and continued throughout the study; (iv) taken melatonin on prescription or purchased; (v) used "sleeping tablets" on prescription or purchased; (vi) diabetes mellitus/diabetes insipidus; and (vii) or if they were pregnant at screening, or of child-bearing potential and unwilling to use contraception. Dipstick urinalysis to exclude urinary tract infection was undertaken at screening. The U.K. National Research Ethics Service Committee South West -- Exeter approved the study protocol (REC reference number: 12/SW/0322).

This was a randomized, double blind, placebo controlled crossover trial with two groups (Fig. [1](#Fig1){ref-type="fig"}). Following an initial four-day pre-treatment monitoring phase, the treatment phases were 2 mg per night of capsulated sustained-release melatonin ('Circadin') or an identical placebo capsule per night for 6 weeks each, separated by a 4 week washout period. Patients were allocated double-blind via a website (<http://www.randomization.com>) to group AB or BA, with unblinding undertaken following database lock and analysis (A = placebo, B = melatonin).Fig. 1Study flow chart

The primary outcome was reduction in nocturia episodes per night, derived from the ICIQ bladder diary (ICIQ-BD) \[[@CR24]\]. Secondary outcomes included; 1. Subjective severity, using the ICIQ tools on nocturia (ICIQ-N) and nocturia quality of life (ICIQ-NQoL) \[[@CR25]\]. 2. MS quality of life, assessed with the MSQoL scale. 3. LUTS, assessed with the ICIQ-MLUTS and ICIQ-FLUTS for males and females respectively. 4. Sleep quality; measured with the Pittsburgh Sleep Quality Index (PSQI). 5. Safety, based on adverse event reporting and Expanded Disability Status Scale (EDSS) score \[[@CR26]\]. Outcome measures were completed at baseline and at the end of each treatment phase. Adverse event reporting was undertaken throughout, and followed up until resolution or for 3 months \[[@CR20]\].

Statistical analysis {#Sec3}
--------------------

We calculated that for a two-sided test, using standard levels of statistical significance (alpha = 0.05), a sample size of *n* = 21 complete data sets would have 80% power to detect a medium to large effect size (Cohen's d = 0.65) with 80% power, and a sample size of *n* = 34 would be needed for a medium effect size (Cohen's d = 0.5) \[[@CR20]\].

The balanced two group, two period, two sequence, double-blind, randomised crossover design with wash-out period comparing treatment to control, ranks highly in the hierarchy of designs. The analyses of the resultant data under this AB/BA design may proceed using nonparametric (Mann-Whitney-Wilcoxon *U*) two-sample statistical techniques which assess for carryover effects, period effects, and treatment effect accounting for any period effects using independent samples designs \[[@CR27]\] or using paired samples in the absence of period and carryover effects. Treatment effect sizes have been quantified and converted to Cohen's *d*. For Cohen's standardized statistic, *d* = 0 indicates the absence of an effect. For statistically significant effects, some broad and cautious threshold guidance to aid interpretation is for, 0 \< *d* \< 0.1 to indicate a trivial effect, 0.1 \< *d* \< 0.3 to indicate a small effect, 0.3 \< *d* \< 0.5 to indicate a moderate effect, 0.5 \< *d* \< 0.8 a medium size effect, 0.8 \< *d* \< 1.3 a large effect, and *d* \> 1.3 a very large effect \[[@CR28]\]. A missing data analysis was also performed on the primary outcome measure to assess sensitivity of statistical conclusions to missingness. This analysis indicated any missing data to be consistent with being missing completely at random (MCAR). Multiple Imputation by Chained Equations (MICE) \[[@CR29]\] with 1000 imputed data sets was performed. These imputed analyses faithfully reproduced the findings from the observed sample data and for brevity of exposition, and to avoid redundancy, are not reported in full.

Results {#Sec4}
=======

In total 13 men and 18 women of mean age 54.8 years (range 34--69) were randomised. Five patients had Primary Progressive MS, 15 patients had Secondary Progressive MS and 11 patients had Relapsing Remitting MS (RRMS). Five of the 11 with RRMS were taking disease modifying therapy at the time of the trial (one interferon beta-1a, two fingolomid and two dimethyl fumarate). Mean EDSS was 4.2 (median 4.0, range 1.5 to 8.0). Five patients withdrew from the trial (Fig. [1](#Fig1){ref-type="fig"}). Reasons for withdrawal were; adverse events (three patients), new-onset unrelated health problems (one patient) and logistic burden (one patient). Mean nocturia severity at baseline from the bladder diary was 1.78 episodes/night and self-reported mean ICIQ symptom score for nocturia was 1.80 episodes/night (range 1--3).

The effects of 2 mg melatonin and placebo on bladder diary parameters are shown in Table [1](#Tab1){ref-type="table"}. There was no significant change seen with melatonin for the primary outcome measure, the number of nocturnal episodes per night. "Objective" nocturia was 1.4/ night for melatonin, compared with 1.6 for placebo (U = 43, *p* = 0.85). Average nocturnal output and nocturnal polyuria index (NPI) were also not significantly altered. Effects on patient-reported LUTS are shown in Table [2](#Tab2){ref-type="table"}. For patient-reported (subjective) nocturia, the number of episodes per night after 6 weeks of melatonin was 3.3, compared with 3.2 with placebo. Overall scores and individual LUTS were not significantly different with melatonin compared with placebo.Table 1Median and range for average number of nocturia episodes, voided output, and NPI by treatment with treatment *p*-value and standardized effect size, *d*MeasureTreatmentBaselineA: PlaceboB: Melatonin*pd*MedianRangeMedianRangeMedianRangeAverage Nocturia Episodes1.701--31.500--31.300--3.30.6180.136Average nocturnal urine output (mls)741310--1416651300--1933667200--11000.9390.02024-h voided volume (mls)21251200--400022131250--39002000881--36000.2540.314Nocturnal Polyuria Index NPI0.320.15--0.710.330.17--0.560.320.15--0.600.8490.052Table 2Median and range of the grouped sub-scores (Voiding and Incontinence) and the individual symptom scores for nocturia, urgency and frequency from the ICIQ LUTS questionnaires (MLUTS and FLUTS for males and females respectively) by treatment, with *p*-values and standardized effect size, *d*MeasureTreatmentA: PlaceboB: Melatonin*pd*MedianRangeMedianRangeVoiding sub-score4.00--122.00--120.0960.492Incontinence (Storage) sub-score3.00--93.00--120.1070.450Nocturia2.01--32.01--30.8920.037Urgency2.00--32.01--40.7720.079

Secondary end points looking at QoL also revealed that melatonin did not significantly affect outcomes. The ICIQ-NQoL questionnaire mean totals were 22.1 for melatonin, compared with 23.6 for placebo (*U* = 41.5, *p* = 0.34; Table [3](#Tab3){ref-type="table"}). For the MSQoL scale (Table [4](#Tab4){ref-type="table"}), there was no significant change between melatonin and placebo in most of the domains, except for physical overall score (50.9 vs. 47.9, respectively, median 48.5 vs 44.0, *U* = 26, *p* = 0.02), role limitations due to physical problems (39.1 vs. 33.3, median 25 vs 12.5, *U* = 29, p = 0.02) and pain score (62.7 vs. 70.6, median 70 vs. 78, *U* = 34.5, *p* = 0.03). In the PSQI (Table [5](#Tab5){ref-type="table"}), the mean scores were 8.1 and 8.7 for melatonin and placebo respectively (median 8.0 vs. 9.0 respectively, *U* = 56.5, *p* = 0.89).Table 3Median and range for ICIQ NQol by treatment with p-value and standardized effect size, *d*MeasureTreatmentA: PlaceboB: Melatonin*pd*MedianRangeMedianRangeOverall score25.08--3520.08--420.3410.261Overall interference5.00--94.00--90.4440.209Sleep/Energy sub-score11.03--1910.03--180.5490.164Bother/Concern sub-score9.54--219.03--160.2880.292Table 4Median and range for MSQoL by treatment, with *p*-value and standardized effect size, *d*MeasureTreatmentA: PlaceboB: Melatonin*pd*MedianRangeMedianRangeMental Overall Score68.016--9275.028--920.1100.446Physical Overall Score44.017--8948.521--900.0230.651Energy Score30.00--7636.00--840.2120.347Emotional Wellbeing68.032--10072.032--1000.9610.013Physical Health45.05--10040.05--1000.7010.105Role limitations due to physical problems12.50--10025.00--1000.0150.701Role limitations due to emotional problems1000--1001000--1000.5800.151Health Perceptions42.55--8545.00--800.3960.233Social Function67.025--10067.00--1000.6030.142Cognitive Function67.00--10073.00--1000.8840.040Health Distress60.015--9060.00--1000.8620.036Change in Health25.00--5050.025--1000.6470.125Quality of Life55.027--9563.00--900.1300.421Pain Score78.00--10070.00--1000.0290.622Table 5Median and range for PSQI by treatment, with *p*-value and standardized effect size, *d*MeasureTreatmentA: PlaceboB: Melatonin*pD*MedianRangeMedianRangeOverall Score9.02--138.02--160.8930.036Sleep Disturbances2.01--32.01--30.0920.471Sleep Medication0.00--00.00--30.2280.333Sleep Duration1.00--31.00--30.6630.119Sleep Latency1.00--51.00--30.9270.025Sleep Quality1.00--31.00--30.9220.027Daytime Dysfunction1.00--31.01--30.1410.410Habitual Sleep Efficiency2.00--31.00--30.1140.440

In all analyses there was little evidence of any carryover effects (i.e. no evidence of period by treatment interaction effects, consistent with a sufficiently large washout period). In addition, the given conclusions for treatment effects are replicated if differences are examined as paired differences using the non-parametric Wilcoxon signed rank test.

Safety {#Sec5}
------

EDSS data is given in Table [6](#Tab6){ref-type="table"}. Overall, there was no difference in EDSS while taking melatonin or placebo; mean score was 4.4 for placebo and 4.7 for melatonin (medians 4.0 and 4.0). Four patients reported worsening symptoms of MS during the study, of which two were taking melatonin at the time. One experienced two separate episodes, once whilst taking melatonin and once whilst taking placebo. One patient experienced Uhthoff's phenomenon, a worsening of neurological condition related to MS, while taking melatonin.Table 6Median and range for EDSS by treatment with *p*-value and standardized effect size, *d*MeasureTreatmentA: PlaceboB: Melatonin*pd*MedianRangeMedianRangeVisual1.00--41.50--40.0560.539Brainstem1.00--21.00--20.2880.292Sensory3.00--43.00--30.0900.474Pyramidal2.00--32.00--30.3860.238Cerebellar2.01--42.00--30.1810.370Cerebral2.00--32.00--30.6530.123Bladder and Bowel2.01--32.00--30.6740.115Ambulatory1.00--91.00--91.000.000EDSS4.01.5--84.03--80.2090.347

Adverse event reporting most commonly identified urinary tract infection (UTI), which affected seven participants. Four of these were prior to receipt of study medication. Three UTIs were found after randomisation. One was on treatment phase 1 and was receiving melatonin. Another had completed treatment phase 2 (placebo). One participant was found to have a UTI after the post drug wash out phase for melatonin.

Two patients experienced faecal urgency; both were no longer taking study medication at the time of onset, and both had been taking placebo.

Two participants experienced lassitude and anergia. One was withdrawn by the clinician, and was found to have been taking placebo. The other had already completed the study, and had been taking melatonin as the most recent study medication.

One patient experienced severe dizziness, and was unblinded and was found to have been taking placebo; this patient was withdrawn from the study. A further patient reported abdominal pain (a reported potential side effect of Melatonin), and was withdrawn by the clinician without unblinding; subsequently the patient was found to have been taking placebo.

Two patients reported chest infections, one taking placebo and the other melatonin. One of these patients went on to report a further three adverse events of pain in fingers, knees and shoulder, which all occurred whilst taking placebo.

One patient experienced abdominal pain resulting in emergency department review, where cholecystitis was diagnosed. She also reported shingles and reduced mobility in separate adverse events. She had been taking the placebo on all of these occasions. One patient reported a probable olecranon bursitis while taking placebo. Colds and an ear infection were reported by two patients; both were taking placebo.

Discussion {#Sec6}
==========

Nocturia is a prominent symptom with substantial detrimental impact on quality of life in MS, especially in light of the range of factors affecting sleep quality in these patients. Ordinarily, there should be a reduction in urine production rate during sleep. Endogenous melatonin is a key contributor in circadian control, and disruption of melatonin is a feature in sleep disturbance in MS \[[@CR30]\]. We surmised that beneficial effects may result indirectly by improved sleep quality, and perhaps directly by some restoration of the normal circadian reduction in urine production at night, and reduced bladder smooth muscle activity. A potential impact of giving supplementary melatonin orally as regulator of circadian rhythms in restoring some measure of circadian control \[[@CR31]\] could be beneficial in the proposed context. In reality, the effect of melatonin in the current study did not identify any reduction in nocturia (either objectively or subjectively). The bladder diary was the main outcome assessment, and during the active treatment phase there was no reduction in nocturia episodes or overall nocturnal urine production.

For the PSQI, the mean scores at the end of the treatment phase were 8.1 for melatonin and 8.7 for placebo. This difference was statistically significant, and seems to indicate worse function with melatonin, but the difference is modest and unlikely to be clinically significant. We also evaluated other aspects of the patient's health and QoL. For the MSQoL, there was no significant change between melatonin and placebo in most of the domains, except that small statistically significant differences were evident in the physical overall score, role limitations due to physical problems, and pain score. It is unclear that this was a definite consequence of melatonin action.

Symptom scores were a key secondary measure, and again melatonin did not appear to have any effect on nocturia specifically or LUTS in general. Nocturia-specific quality of life did not show any evident improvement. Nocturia has a multifactorial pathophysiology, which potentially could mean that melatonin might have effect in some individuals and not others, and this was considered to explain the finding of a responder group in a previous study which examined melatonin use for treatment of nocturia in men with benign prostate enlargement \[[@CR15]\]. However, there did not seem to be any evident responder group in the current study.

The lack of evident difference between melatonin and placebo may reflect the pragmatic approach taken in the study. Diabetes mellitus and diabetes insipidus were excluded, but otherwise inclusive criteria were used for study recruitment. This pragmatic approach was taken to reflect the utility of a therapy which could be applied to the majority of patients in the general healthcare context, without having to undertake too much clinical assessment. The fact that we did not identify benefit could reflect the wide range of potential co-morbidity in MS, indicating that it is likely that assessment of specific underlying mechanisms probably is needed to understand nocturia in MS. A low dose of melatonin was chosen (2 mg), because at the time the study was designed there was discussion that melatonin could potentially contribute to deterioration in MS severity through effects on immune function \[[@CR32]\]. Based on the results, it seems that this low dose was insufficient for nocturia therapy, even though it is a standard dose for treating sleep disorders in a wider population. Some studies have used higher doses of melatonin in an MS population, demonstrating improved sleep quality \[[@CR19]\]. Recent literature does not identify detrimental effect of melatonin on MS severity, and alternative hypotheses have been promulgated regarding a potential beneficial effect. We did not measure endogenous melatonin production, or effective serum melatonin levels on treated patients, so we are unable to state whether serum levels of the hormone reached therapeutic levels in our study population.

The inclusion of a placebo group is an essential part of LUTS investigation, since placebo responses are noted to be rather big generally \[[@CR33]\]. In the current study, the placebo response seen in the bladder diaries and symptom scores was modest. Undertaking observations such as bladder diaries is considered a potential factor that could influence patient behaviour, since completing a bladder diary shows to a patient when they are generating a high urine output, which can feed back on their behaviour. This was not a particular observation in the current study, where the baseline 24 h voided volume was 2.2 L, and was similar during the treatment phases (2.2 L for placebo, and 2.0 L per 24 h for melatonin, medians 2.1 L, 2.2 L, and 2.0 L respectively). The nocturnal polyuria index was unchanged (median 0.32, 0.33, 0.32 for baseline, placebo and melatonin respectively). A small reduction in median nocturnal urine output was seen (baseline 741 mL, placebo 651 mL, and melatonin 667 mL), but this was not statistically significant. It did not yield a significant change in nocturia episodes (median 1.70, 1.50 and 1.30 respectively).

There was no clear adverse safety signal. No adverse events appeared to have any clear link to the melatonin therapy on a consistent basis. UTIs were reported, and two episodes of faecal urgency. Single presentations with Uhthoff's phenomenon, feeling drained, cold hands, profound somnolence, and others were also described. The qualitative interviews also identified that fatigue was a key feature. The individual with Uhthoff's phenomenon explains the difference in the visual domain on the EDSS scores, which were otherwise not significantly different for the melatonin and placebo phases.

Conclusions {#Sec7}
===========

In summary, a low dose of melatonin taken at bedtime may be an ineffective therapy for nocturia in MS, studying an adult population with nocturia once per night or more often. A different dose regime of melatonin or recruitment selection criteria would need to considered to ascertain whether melatonin could influence nocturia in MS.
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:   Frequency volume chart
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ICIQ-MLUTS

:   Male-specific tool for assessing severity and bother of all LUTS

ICIQ-N
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ICIQ-NQoL

:   A nocturia-specific quality of life tool which will be used throughout the study

LUTS

:   Lower urinary tract symptoms

MeNiMS

:   Study Acronym: Melatonin for Nocturia in Multiple Sclerosis
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:   Multiple sclerosis
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